Recent findings in CDAHFD-treated mice suggested that proteins vitronectin (VN), monoacylglycerol acyltransferase 2 (MGAT2), retinoic acid-inducible gene-I (RIG-I)-like receptor (RLR), and formyl peptide receptor 2 (FPR2) may become potential diagnostic biomarkers and/or promising therapeutic opportunities for NAFLD/NASH by modulating the inflammatory reaction and contributing to the development of fibrosis via the activation of HSCs [35,36,37,38] (Table 1 and Table 2). The gene discussed is FPR2; the disease is metabolic dysfunction-associated steatotic liver disease.